<DOC>
	<DOCNO>NCT02442648</DOCNO>
	<brief_summary>The primary purpose study provide preliminary evaluation safety potential efficacy carfilzomib reduce HLA antibody level highly sensitize kidney transplant candidate .</brief_summary>
	<brief_title>B-Cell Targeted Carfilzomib Desensitization</brief_title>
	<detailed_description>This study non-randomized , open label , iterative pilot study . The duration study include 16 month enrollment period 5 6 month follow-up . A total 32 patient , male female , age 18 65 enrol .</detailed_description>
	<criteria>1 . Patient 18 65 year age , inclusive . 2 . Voluntary write informed consent . 3 . Female subject either postmenopausal least 1 year prior initiation study treatment , surgically sterilize , childbearing potential , agree practice 2 effective method contraception 3 month last dose carfilzomib . 4 . Male subject , even surgically sterilize ( i.e . status postvasectomy ) must agree 1 effective contraception . 5 . Patient eligible living donor : 1 ) positive cytotoxic crossmatch , 2 ) moderate strongly positive T B cell flow cytometry crossmatch ( confirm donorspecific antibody ( DSAs ) solidphase assay screening , 3 ) &gt; 2 low moderate level DSAs ( DSA value 1500 8000 MFI ) . 6 . LVEF ≥ 45 % within 3 month evaluation . 7 . Patient kidney transplant wait list await decease donor transplant current peak cytotoxic calculate panel reactive antibody ( PRA ) &gt; 30 % . 8 . Patient must know contraindication treatment carfilzomib rituximab . 9. Review pretransplant medical clearance patient 's dialysis nephrologist transplant nephrologist treat physician assure patient medically acceptable study entry . 10 . Patient must vaccinate hepatitis B virus . 1 . Patient significant neuropathy ( Grades 3 4 , Grade 2 pain ) CTCAE criterion within 14 day enrollment . 2 . Myocardial infarction within 6 month prior enrollment ADQI Heart Failure ESRD Classification System Class 2NR great ( Appendix B ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . 3 . Patient receive investigational drug within 14 day prior initiation study treatment . 4 . Serious medical psychiatric illness likely interfere participation clinical study . 5 . Diagnosed treat another malignancy within 2 year enrollment , exception : 1 ) complete resection basal cell carcinoma squamous cell carcinoma skin , 2 ) situ malignancy , 3 ) lowrisk prostate cancer curative therapy , 4 ) cancer cure rate ≥ 99 % . 6 . History severe allergic anaphylactic reaction humanize murine monoclonal antibody . 7 . Known history allergy Captisol® ( cyclodextrin derivative use solubilize carfilzomib ) 8 . Patients hemoglobin count &lt; 8 g/dL ( 80 g/L ) ( subject may receive red blood cell [ RBC ] transfusion accordance institutional guideline ) , absolute neutrophil count &lt; 1,000/mm3 platelet count &lt; 75,000/mm3 within 14 day consent . 9 . Patients antiHIVpositive , HBsAgpositive , antiHCV positive testing perform within one year consent . 10 . Patients current recent severe systemic infection require treatment ( systemic antibiotic , antiviral , antifungal ) within 2 week prior initiation study treatment . 11 . Receipt live vaccine within 4 week prior initiation study treatment . 12 . Evidence severe liver disease medical history physical exam abnormal liver profile ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] total bilirubin &gt; 1.5 time upper limit normal [ ULN ] ) test perform within 30 day consent . 13 . Female subject pregnant breastfeeding . 14 . Any clinically significant medical disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent . 15 . Patient yet dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Renal Transplantation</keyword>
	<keyword>Carfilzomib</keyword>
	<keyword>Kyprolis</keyword>
	<keyword>Desensitization</keyword>
</DOC>